trending Market Intelligence /marketintelligence/en/news-insights/trending/Ms4QKiu6XHr-RN7_wC8aHg2 content esgSubNav
In This List

G&E Herbal Biotechnology Q2 loss narrows YOY

Blog

Insight Weekly: Labor market recovery hurdles; power market integration; nonbank M&A hunt

Blog

Investment Banking Essentials Newsletter: October Edition

Blog

Banking Essentials Newsletter: October Edition

Blog

ESG & Technology: Impacts and Implications


G&E Herbal Biotechnology Q2 loss narrows YOY

G&E Herbal Biotechnology Co. Ltd. said its normalized net income for the second quarter amounted to a loss of 4 Taiwan cents per share, compared with a loss of 9 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$2.1 million, compared with a loss of NT$5.2 million in the year-earlier period.

The normalized profit margin increased to negative 19.3% from negative 69.9% in the year-earlier period.

Total revenue grew 46.0% year over year to NT$10.9 million from NT$7.5 million, and total operating expenses declined 10.8% year over year to NT$18.7 million from NT$20.9 million.

Reported net income totaled a loss of NT$3.9 million, or a loss of 7 cents per share, compared to a loss of NT$7.0 million, or a loss of 12 cents per share, in the year-earlier period.

As of Aug. 12, US$1 was equivalent to NT$31.39.